Meropenem drugs uses indications contraindications how to give how to dilute
Reading File
Reading File
Finding Sources
Searching PubMed
meropenem AND administration
Searching the Web
Merrem IV prescribing information dilution administration infusion 2025 meropenem
Reading File
Reading Web Page
https://labeling.pfizer.com/ShowLabeling.aspx?id=9318
Finding Sources
Reading File
Meropenem
Meropenem is a broad-spectrum carbapenem antibiotic given only by IV. It kills susceptible bacteria by inhibiting bacterial cell-wall synthesis. It has good Gram-negative and anaerobic coverage, including many ESBL-producing organisms and Pseudomonas aeruginosa, but it does not reliably treat MRSA, Enterococcus faecium, atypical bacteria, or carbapenemase-producing organisms. Goodman & Gilman's pharmacology text describes its usual role in serious hospital-onset respiratory, gastrointestinal, and urinary infections. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, p. 1179.
Uses / indications
Use only when infection is proven or strongly suspected to be bacterial and susceptible, ideally guided by culture results.
Common clinical uses include:
- Severe hospital-acquired or ventilator-associated pneumonia, especially when resistant Gram-negative organisms are suspected
- Complicated intra-abdominal infection, including perforation, peritonitis, or intra-abdominal abscess
- Complicated urinary tract infection / pyelonephritis, including ESBL-producing Enterobacterales when susceptible
- Severe complicated skin and soft-tissue infection
- Sepsis caused by susceptible bacteria
- Bacterial meningitis when a carbapenem is indicated, often in specialist-directed treatment. Meropenem has lower seizure risk than imipenem and reaches the CNS. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, p. 1179.
- Febrile neutropenia or other severe infections in immunocompromised patients, per local protocol
The US product label specifically includes complicated skin/skin-structure infection, complicated intra-abdominal infection, and bacterial meningitis in children aged 3 months or older. See the Merrem IV prescribing information.
Usual adult dosing
Dose must be individualized by infection, organism MIC, weight, and kidney function.
Typical adult dosing with normal renal function:
- 500 mg IV every 8 hours: some skin/soft-tissue infections
- 1 g IV every 8 hours: many serious intra-abdominal, urinary, pulmonary, and sepsis infections
- 2 g IV every 8 hours: commonly used by specialist protocols for meningitis or selected severe CNS infections
Standard infusion is usually over 15-30 minutes. In selected severe resistant Gram-negative infections, an extended infusion over 3 hours may be ordered to improve time above the MIC. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, p. 1179.
Renal adjustment
Meropenem is cleared by the kidneys. Check serum creatinine and calculate creatinine clearance before prescribing.
For standard adult dosing:
| Creatinine clearance | Adjustment |
|---|---|
| >50 mL/min | Usual dose every 8 h |
| 26-50 mL/min | Usual dose every 12 h |
| 10-25 mL/min | Half usual dose every 12 h |
| <10 mL/min | Half usual dose every 24 h |
Use your hospital guideline or pharmacist for dialysis, CRRT, obesity, augmented renal clearance, children, and meningitis dosing.
Contraindications
Do not give meropenem to a patient with:
- Known serious allergy to meropenem, another carbapenem, or a component of the product
- Previous anaphylaxis to a beta-lactam antibiotic, unless a specialist has assessed and planned an alternative/test-dose strategy
The labeled contraindication is known hypersensitivity to the product/class or prior anaphylactic reaction to beta-lactams. See the official contraindications and warnings.
Important precautions
Use carefully, or seek prescriber/pharmacist advice, if the patient has:
- Renal impairment: dose reduction is required
- History of seizures, epilepsy, or CNS disease
- Severe penicillin or cephalosporin allergy
- Current or previous Clostridioides difficile diarrhea
- Pregnancy or breastfeeding: assess indication and alternatives
- Concomitant valproic acid/divalproex: avoid if possible. Carbapenems can markedly reduce valproate concentrations and can cause breakthrough seizures. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, p. 1179.
- Probenecid use: it increases meropenem exposure and is generally avoided.
Stop the infusion and obtain urgent help for anaphylaxis, severe rash or blistering, facial swelling, wheeze, severe diarrhea, or a seizure.
How to prepare and dilute IV meropenem
Follow the exact brand, vial type, local policy, aseptic technique, and pharmacy instructions. Do not use a prepared solution that is cloudy, discolored, or contains particles.
1. Reconstitution for IV bolus/push
For injection vials:
- 500 mg vial: add 10 mL sterile water for injection
- 1 g vial: add 20 mL sterile water for injection
This produces approximately 50 mg/mL. Gently shake until dissolved and allow to stand until clear.
2. Further dilution for IV infusion
After reconstitution, further dilute in a compatible infusion solution to a final concentration of about 1-20 mg/mL.
Common compatible diluents:
- 0.9% sodium chloride (normal saline)
- 5% dextrose in water (D5W)
Example:
- For 1 g, reconstitute with 20 mL sterile water, then add to a compatible IV bag, commonly 50-100 mL depending on the local protocol.
- For 500 mg, reconstitute with 10 mL sterile water, then add to a compatible IV bag.
3. Administration
- IV infusion: administer over 15-30 minutes.
- Extended infusion: only if specifically ordered, commonly over 3 hours.
- IV push/bolus: some product labels allow up to 1 g given slowly over 3-5 minutes, but many facilities prefer infusion for routine administration.
- Do not give IM.
- Do not mix meropenem in the same syringe, bag, or line with another medicine unless compatibility has been verified. Flush the line before and after if needed.
The manufacturer’s preparation instructions specify 10 mL sterile water for a 500 mg vial and 20 mL for a 1 g vial; standard infusion is 15-30 minutes. See the manufacturer preparation instructions.
Monitoring during treatment
- Culture and susceptibility results, then de-escalate antibiotic if possible
- Temperature, WBC count, blood pressure, clinical response
- Renal function and urine output
- Rash or allergic reaction
- Diarrhea, particularly severe or persistent diarrhea
- Seizure or altered mental status, especially in renal dysfunction
- CBC and liver tests during prolonged therapy
A 2024 systematic review evaluated continuous versus intermittent meropenem administration, but this does not replace local IV stability and antimicrobial-stewardship protocols (PMID 38525074).
This is a shared conversation. Sign in to Orris to start your own chat.